<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05079763</url>
  </required_header>
  <id_info>
    <org_study_id>UPMREB 2021-140-01</org_study_id>
    <nct_id>NCT05079763</nct_id>
  </id_info>
  <brief_title>Bacterial Cellulose-monolaurin Hydrogel for Acute Radiation Dermatitis</brief_title>
  <official_title>Bacterial Cellulose-monolaurin Hydrogel for Preventing Therapy-induced High-grade Acute Dermatitis Among Filipinos With Breast Adenocarcinoma: a Pilot Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of the Philippines</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of the Philippines</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute radiation dermatitis (ARD) is almost universally experienced by patients with cancer&#xD;
      during or after radiation therapy. This condition potebtxallt leads to detrimental clinical&#xD;
      outcomes as it adversely affects adherence to prescribed subsequent management and further&#xD;
      worsens quality of life. Nevertheless, there remains no consensus on the appropriate&#xD;
      intervention for ARD. This pilot two parallel-group randomized trial aims to clinically&#xD;
      assess the potential of bacterial cellulose-monolaurin hydrogel, compared to placebo cream,&#xD;
      to prevent high-grade ARD among Filipinos with breast cancer up to four weeks after last&#xD;
      radiotherapy session.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of high grade acute radiation dermatitis</measure>
    <time_frame>Baseline to Week 4 post-radiotherapy</time_frame>
    <description>High-grade acute radiation dermatitis is defined as Common Terminology Criteria for Adverse Events (CTCAE) grade of at least 3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distribution of participants in terms of ARD CTCAE grades</measure>
    <time_frame>Baseline to Week 4 post-radiotherapy</time_frame>
    <description>Distribution of participants across the ARD CTCAE grades (0-5) in the two interventions will be compared</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported quality of life</measure>
    <time_frame>Baseline to Week 4 post-radiotherapy</time_frame>
    <description>Outcome will be assessed using the Skindex-16 (SD-16) questionnaire, administered on a weekly basis from baseline up to two weeks post-radiotherapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Acute Radiation Dermatitis</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Application of bacterial cellulose-monolaurin hydrogel in the prescribed area for every 12 hours starting from receipt of first radiotherapy until development of moist desquamation or two week after completion of radiotherapy plan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Application of placebo cream in the prescribed area for every 12 hours starting from receipt of first radiotherapy until development of moist desquamation or two week after completion of radiotherapy plan</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bacterial cellulose-monolaurin hydrogel</intervention_name>
    <description>Hydrogel containing Komagataeibacter bylines-derived bacterial cellulose, virgin coconut oil monolaurin, cucumber fragrance and distilled water</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo cream</intervention_name>
    <description>Cream containing distilled water, white petrolatum, steady alcohol, propylene glycol, sodium laurel sulphate, methylparaben and propylparaben</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female sex at birth&#xD;
&#xD;
          -  Age at least 18 years at the time of invitation&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status score of either 0 or 1&#xD;
&#xD;
          -  With histopathologic diagnosis of breast carcinoma&#xD;
&#xD;
          -  Already completed prescribed mastectomy and chemotherapy (adjuvant or neoadjuvant)&#xD;
             interventions&#xD;
&#xD;
          -  Scheduled to receive hypo fractionated postmastectomy-postchemotherapy radiation&#xD;
             therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  With concurrent or previous history of any malignancy&#xD;
&#xD;
          -  With history of mediastinal or thoracic irradiation&#xD;
&#xD;
          -  With current bilateral synchronous breast carcinoma&#xD;
&#xD;
          -  With diagnosis of metastases from any form of breast cancer&#xD;
&#xD;
          -  With any skin lesion in the planned radiation field deemed deramtologically and/or&#xD;
             radiotherapeutically relevant&#xD;
&#xD;
          -  With concomitant disease states deemed clinically significant (connective tissue&#xD;
             diseases, infections, uncontrolled chronic disorders, renal failure, hepatic&#xD;
             dysfunction, etc.)&#xD;
&#xD;
          -  With known history of hypersensitivities and/or reactions against any component of&#xD;
             either experimental or comparator interventions&#xD;
&#xD;
          -  Inability to personally provide informed consent or to personally comply with skin&#xD;
             care instructions&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Soraya Elisse Escandor, MD</last_name>
    <phone>+639155753928</phone>
    <email>seescandor@up.edu.ph</email>
  </overall_contact>
  <location>
    <facility>
      <name>Philippine General Hospital</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudine Yap-Silva, MD</last_name>
      <phone>+63285548400</phone>
      <email>dermatology.uppgh@up.edu.ph</email>
    </contact>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 4, 2021</study_first_submitted>
  <study_first_submitted_qc>October 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ARD</keyword>
  <keyword>postmastectomy</keyword>
  <keyword>breast cancer</keyword>
  <keyword>breast adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Radiodermatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Monolaurin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

